The production approval document of the new gastroulcer drug polyprizine granules of HISCO in about 3 months

According to the website of the State Food and Drug Administration (CFDA) on December 9, the status of the three digestive drugs of Hisilicon polyprizine granules changed to "under approval", which means that the drug has passed the technical review and production site inspection, and entered the final approval stage, and is expected to obtain the production approval document in about three months Deng Xiang, the company's board secretary, has said that after the drug is listed, the guaranteed sales revenue will reach 300 million yuan The main component of polyprizine granules is polyprizine, which is used for the treatment of gastric ulcer This product is the only new type of gastric mucosa protective agent with multi-layer repair mechanism and long-term physical coverage, which can effectively reduce the recurrence rate of ulcer It is significantly superior to the traditional gastric mucosa protective agent in terms of safety, and is listed as one of the "top ten prescription drugs in China in 2012" Polyprizin is a new generation of anti gastric ulcer drug developed by hamari new drug industry Co., Ltd in Japan It is the first zinc containing compound for clinical use It passed the review of Japan's Ministry of health and health in 1994 In China, at present, only Jilin Boda Weiye Pharmaceutical Co., Ltd is a manufacturer of jupurui zinc granules This year, HISCO has invested a lot in R & D and new products According to the 2014 half year report, in the first half of 2014, the company achieved revenue of 531 million yuan, a year-on-year increase of 16.45%; and net profit of 232 million yuan, a slight increase of 2.01% From January to June this year, the company's R & D investment reached 88.59 million yuan, an increase of 75% compared with 50.44 million yuan in the same period last year; meanwhile, due to the listing of new products, the company increased its market development efforts, and the sales expense reached 82.36 million yuan, an increase of 39% compared with the same period last year.